Netherlands· NL-bc8d1f8c8d78
Anoro Ellipta 55 microgram/22 microgram inhalatiepoeder, voorverdeeld
A vilanterol und umeclidinium bromid product containing umeclidiniumbromide + vilanteroltrifenataat, registered in Netherlands by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Vilanterol und umeclidinium bromid is registered in 11 of 19 countries.
Countries holding a registration under ATC R03AL03 (vilanterol und umeclidinium bromid), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Vilanterol und umeclidinium bromid · ATC R03AL03
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- UMECLIDINIUMBROMIDE + VILANTEROLTRIFENATAAT
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Netherlands (NL)
- ATC code
- R03AL03
- ATC class
- Vilanterol und Umeclidinium bromid
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/14/898
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vilanterol und umeclidinium bromid in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainANORO ELLIPTA 55 MCG/22 MCG POLVO PARA INHALACION (UNIDOSIS)Glaxosmithkline (Ireland) Limited
- FinlandANORO ELLIPTAOrifarm Oy
- United KingdomAnoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhalerPharmaram Ltd
- SwedenANORO ELLIPTA 55 mikrogram/22 mikrogram Inhalationspulver, avdelad dosGlaxoSmithKline Trading Services Ltd
- SwitzerlandAnoro Ellipta
- PolandAnoro ElliptaGlaxoSmithKline (Ireland) Limited
- NorwayAnoro ElliptaGlaxoSmithKline (Ireland) Limited
- CanadaANORO ELLIPTAGLAXOSMITHKLINE INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Anoro Ellipta, Laventair Ellipta
- Liechtenstein · Anoro Ellipta, Laventair Ellipta
- Norway · Anoro Ellipta, Laventair Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/96309c1b-ccdc-493d-9dda-ba8620801b93 GET /v1/drugs/96309c1b-ccdc-493d-9dda-ba8620801b93?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Inhalatiepoeder, voorverdeeld",
"route": "Inhalatie",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/anoro-ellipta-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Vilanterol and umeclidinium bromide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp113416",
"excipients": [
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)"
],
"substances": [
"UMECLIDINIUMBROMIDE",
"VILANTEROLTRIFENATAAT"
],
"leaflet_url": null,
"authorised_at": "2014/05/08",
"procedure_number": "EMEA/H/C/002751",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/14/898",
"additional_monitoring": "N"
}See everything about vilanterol und umeclidinium bromid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.